Clinical trial
(H-49235) Trivalent Autologous T-Lymphocytes Co-Expressing Three Chimeric Antigen Receptors Targeting CD19, CD20 AND CD22 in Acute B-lineage Leukemia (TRICAR-ALL)
NCT05010564 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- (H-49235) Trivalent Autologous T-Lymphocytes Co-Expressing Three Chimeric Antigen Receptors Targeting CD19, CD20 AND CD22 in Acute B-lineage Leukemia (TRICAR-ALL)
- Lead sponsor
- Baylor College of Medicine
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- July 18, 2023
- Completion date
- March 29, 2040
- Enrollment
- 38 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.